Focused On-demand Library for Protein phosphatase 1H

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9ULR3

UPID:
PPM1H_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9ULR3; B1Q2A9; B2RXG4; Q6PI86

BACKGROUND:
The enzyme Protein phosphatase 1H, with the unique identifier Q9ULR3, is integral to the regulation of the cell cycle. It achieves this by dephosphorylating CDKN1B at 'Thr-187', a critical modification that prevents CDKN1B from being marked for degradation via the proteasome pathway.

THERAPEUTIC SIGNIFICANCE:
The exploration of Protein phosphatase 1H's function offers a promising avenue for the development of novel therapeutic approaches. By modulating its activity, researchers may unlock new strategies to manage diseases characterized by abnormal cell growth.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.